中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (3): 234-238.doi: 10.12144/zgmfskin202503234

• 综述 • 上一篇    

寻常型天疱疮的治疗进展

陈琰1,张佩莲1,2   

  1. 1云南中医药大学第一附属医院，云南昆明，650021；2云南省中医医院，云南昆明，650021
  • 出版日期:2025-03-15 发布日期:2025-03-03

Progress in the treatment of pemphigus vulgaris

CHEN Yan1, ZHANG Peilian1,2   

  1. 1 First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming 650021, China; 2 Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650021, China
  • Online:2025-03-15 Published:2025-03-03

PDF (PC)

31

摘要： 寻常型天疱疮(pemphigus vulgaris,PV)是天疱疮中最常见的类型。利妥昔单抗在国外指南已推荐为一线治疗，但在我国推荐为中重度PV的二线治疗。随着对PV发病机制的深入研究，发现针对新治疗靶点的药物，如新型的生物制剂、B细胞激活因子和增殖诱导配体抑制剂、T细胞免疫疗法、JAK抑制剂等，本文对上述疗法的进展进行综述，为临床提供更多的治疗选择。

关键词: 寻常型天疱疮, 抗CD20单抗, B细胞激活因子, 增殖诱导配体, T细胞免疫, JAK抑制剂

Abstract: Pemphigus vulgaris (PV) is the most common type of pemphigus. Rituximab has been recommended as first-line therapy in foreign guidelines, but in our country it is recommended as second-line therapy for moderate to severe PV. With the further study of the pathogenesis of PV, some new therapeutic targets have been found that may play a role in the treatment of PV, for example, new biological agents, inhibitors of B-cell activating factor and proliferation-inducing ligand, T-cell immunotherapy, JAK inhibitors, etc. , will provide more treatment options for the clinics.

Key words: pemphigus vulgaris, anti-CD20 monoclonal antibody, B cell activator, proliferation-induced ligand, T-cell immunity, JAK inhibitor